ArticleIn silico pharmacology2025
Pharmacological mechanisms of
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Bioactive compounds of GG were retrieved from IMPPAT, TCMSP, and TCM databases. Predicted targets were obtained from Swiss Target Prediction and STITCH, while PU-related targets were collected from DisGeNet, OMIM, and Gene Cards. Common targets between GG and PU underwent GO and KEGG enrichment analysis, and networks were visualized using Cytoscape 3.10.1. Molecular docking and In Vitro studies were conducted for validation. Results: Network analysis identified 29 phytochemicals and 157 common GG-PU target genes. Key hub genes, including IL6, TP53, AKT1, STAT3 and TNF, were involved in inflammation, apoptosis, and tissue repair. Pathway enrichment suggested GG's anti-PU effects via the PI3K-Akt pathway. Molecular docking confirmed strong binding affinities, supported by In Vitro studies. Conclusion: GG exerts anti-PU effects through multi-target interactions, particularly via the PI3K-Akt signaling pathway. Quercetin is the major phytoconstituent showing interactions with multiple PU-related targets and exhibited the highest binding affinity. However, further in vivo and clinical studies are required to validate its full therapeutic potential. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00429-y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.